Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 9:43 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–17 of 17 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Refresh Plus Lubricant Eye Drops Clear all
Terminated Phase 1Phase 2 Interventional Results available

Brimonidine Eye Drops for Treatment of Ocular Graft-vs-Host Disease (oGVHD)

NCT02975557
View directory record Official record
Conditions
Dry Eye, Ocular Graft vs Host Disease, Meibomian Gland Dysfunction
Interventions
Brimonidine 0.15%, Brimonidine 0.075%, Placebo
Drug
Lead sponsor
Sandeep Jain, MD
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluate the Safety and Efficacy of a New Artificial Tear for Use After LASIK Surgery

NCT00544713
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2011 · Synced Sep 3, 2026, 9:43 AM EDT
Recruiting Phase 4 Interventional

Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Functional Outcomes With the Use of OTC Lubricating Eye Drops in Subjects With Dry Eye Disease

NCT07676084
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
Preservative Free Polyethylene glycol 400 0.25%, Propylene Glycol (0.6%), Carboxymethylcellulose sodium 0.5%, Glycerin 1.0%, Polysorbate 80 0.5%
Drug
Lead sponsor
Andover Research Eye Institute
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Not applicable Interventional Results available

Safety and Efficacy of an Artificial Tear for the Treatment of Dry Eye

NCT00514852
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
Carboxymethylcellulose and Glycerin based artificial tear, Carboxymethylcellulose
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Results available

Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy

NCT02121847
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
cyclosporine 0.05% ophthalmic emulsion, carboxymethylcellulose-based lubricant eye drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cool vs Room-temperature Artificial Tears

NCT05832996
View directory record Official record
Conditions
Diabetic Retinopathy With Macular Edema of Both Eyes (Diagnosis), Central Retinal Vein Occlusion With Macular Edema, Exudative Age-Related Macular Degeneration, Unspecified Eye, Cystoid Macular Edema, Ocular Surface Disease, Dry Eye Sensation, Eye Pain
Interventions
Refresh Plus Preservative-free Lubricant Eye Drops
Drug
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 105 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Fluorophotometry Evaluation of Lubricant Eye Drops

NCT00347854
View directory record Official record
Conditions
Healthy
Interventions
Systane Free lubricant eye drops, Visine Tears Lubricant Eye Drops, Refresh Liquigel Lubricant Eye Drops, Refresh Plus Lubricant Eye Drops
Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 3, 2026, 9:43 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Tear Osmolarity Over Time With Artificial Tears

NCT01227226
View directory record Official record
Conditions
Dry Eye
Interventions
Artificial tears
Drug
Lead sponsor
Hom, Milton M., OD, FAAO
Individual
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Azusa, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2011 · Synced Sep 3, 2026, 9:43 AM EDT
Active, not recruiting Phase 3 Interventional

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

NCT07284381
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ABBV-444, REFRESH OPTIVE UD
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
261 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
20
States / cities
Dothan, Alabama • Chandler, Arizona • Azusa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Tear Lipid Layer Thickness With Emollient Eye Drops

NCT03380624
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Refresh Optive, Refresh Optive MEGA-3
Drug
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of a New Artificial Tear Formulation Compared With Systane Ultra Multidose in Participants With Dry Eye Disease

NCT04393441
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
011516X (New Artificial Tear Formulation), Systane Ultra Multidose, REFRESH PLUS®
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
26
States / cities
Azusa, California • Glendale, California • Newport Beach, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Carboxymethylcellulose Artificial Tears on the Eye Microbiome

NCT05292755
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose (CMC) Artificial Tears, Preservative-free, CMC-free Artificial Tears (control)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

NCT06544694
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial Tears
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Louisville, Kentucky • Garner, North Carolina • Leland, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease

NCT01459588
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Carboxymethylcellulose Based Eye Drop Formulation A, Carboxymethylcellulose Based Eye Drop Formulation B, Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops, Carboxymethylcellulose Based Lubricant Eye Drops
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Petaluma, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Sep 3, 2026, 9:43 AM EDT
Terminated Not applicable Interventional Results available

The Effects of Cyclosporin A in a Low Humidity Environment, on the Ocular Surface

NCT02199964
View directory record Official record
Conditions
Dry Eye
Interventions
Cyclosporin 0.05% emulsion, Endura, Refresh artificial tears
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2020 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

NCT06660290
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, Artificial tears
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
6
States / cities
Newport Beach, California • Colorado Springs, Colorado • Andover, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 3, 2026, 9:43 AM EDT
Completed Phase 1 Interventional

INflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study

NCT04505566
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Ketorolac 0.45% ophthalmic solution, Placebo - Preservative-free artificial tears, Aqueous PGE2 and inflammatory cytokines measurements
Drug · Other
Lead sponsor
Stephen J. Kim, MD
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 3, 2026, 9:43 AM EDT